You are here: Industry Insights > Roche

News List

Roche gets UK and US clearances for Spark Therapeutics acquisition pharmaceutical-technology
December 18, 2019
Swiss healthcare company Roche has received clearances in the UK and US for its proposed acquisition of US-based gene therapy company Spark Therapeutics for $4.8bn.
Data shows non-inferiority of SC administration of Roche’s Perjeta and Herceptin pharmaceutical-technology
December 16, 2019
Roche has published data demonstrating non-inferiority of a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) administered through ...
SABCS: Roche's Perjeta builds case as HER2-positive add-on fiercepharma
December 12, 2019
Roche is in the hot seat as its longtime breast cancer blockbuster Herceptin faces a growing stable of biosimilar challengers. But other drugs in Roche's portfolio are on the rise.
Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis worldpharmanews
September 17, 2019
Roche announced longer-term data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO showed that patients who were treated with OCREVUS® (ocrelizumab) continuously for ...
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. worldpharmanews
September 04, 2019
Roche and Spark Therapeutics, Inc. (NASDAQ: ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares...
EC approves Roche’s Tecentriq combination to treat breast cancer pharmaceutical-technology
September 03, 2019
Roche has gained approval from the European Commission (EC) for Tecentriq (atezolizumab) with chemotherapy (Abraxane) to treat patients with unresectable locally advanced or...
Roche's Tecentriq grabs I-O's first European OK for triple-negative breast cancer fiercepharma
September 02, 2019
Back in March, Roche’s Tecentriq led its class of immuno-oncology drugs into the triple-negative breast cancer arena (TNBC), picking up the first FDA OK in the tough-to-treat disease. Now, it’s done the same across the pond.
Roche’s Tecentriq/Abraxane Combo for TNBC Approved by EU contractpharma
August 30, 2019
The Tecentriq combination marks the first cancer immunotherapy regimen to be available in Europe for triple-negative breast cancer.
NHS England expands funding of Roche’s Hemlibra for haemophilia A pharmaceutical-technology
August 23, 2019
NHS England has announced it will reimburse Hemlibra (emicizumab) for severe congenital haemophilia A patients without clotting protein factor VIII inhibitors.
Dr Reddy’s launches Roche’s Avastin biosimilar in India expresspharma
August 21, 2019
Drug firm Dr Reddy’s Laboratories said it has launched a biosimilar of Roche’s Avastin in India indicated for the treatment of various types of cancers. The company’s biosimilar, Versavo, is available in ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page